KDIGO Conversations in Nephrology

In Episode 34, the first in a three-part Conversations in Nephrology series on IgA nephropathy (IgAN), host Brad Rovin, MD (The Ohio State University), KDIGO IgAN/IgAV Guideline Co-Chair, is joined by Dana Rizk, MD (University of Alabama at Birmingham), to explore the rationale for complement inhibition in the management of IgAN.
Dr. Rovin and Dr. Rizk examine the evidence linking the complement system to IgAN, drawing on experimental research and genome-wide association studies. They discuss the roles of the lectin, alternative, and terminal complement pathways and the rationale for targeting complement in the management of IgAN.
The series continues with upcoming episodes featuring Andrew Bomback, MD (Columbia University Irving Medical Center), on building a patient profile for complement inhibition and Sayna Norouzi, MD (Loma Linda University Medical Center), on where complement inhibitors fit within the IgAN therapeutic toolbox.

In the third episode of the KDIGO Conversations in Nephrology FSGS series, host Dr. Kirk Campbell (University of Pennsylvania) sits down with world-renowned glomerular disease expert Dr. Jai Radhakrishnan (Columbia University) to navigate the shifting landscape of Focal Segmental Glomerulosclerosis (FSGS) management.
The conversation dives deep into the diagnostic complexities of FSGS, moving beyond histological patterns to understand the diverse drivers of podocyte injury. Dr. Radhakrishnan shares his practical clinical algorithm, offering a roadmap for balancing supportive care, selective immunosuppression, and the integration of novel, non-immunosuppressive therapies. Join Drs. Campbell and Radhakrishnan as they discuss the robust pipeline of emerging agents in this field.

In this second episode of the three-part KDIGO Conversations in Nephrology series, Dr. Kirk Campbell speaks with Dr. Laura Mariani about the central role of proteinuria reduction in the management of focal segmental glomerulosclerosis (FSGS).

The discussion explores the biologic link between podocyte injury and proteinuria, the goals and findings of the PARASOL initiative, and how proteinuria may help guide clinical trial design and treatment decisions in FSGS. Dr. Mariani also reflects on the importance of collaboration and data sharing in advancing therapies for rare glomerular diseases.

Join Dr. Kirk Campbell (University of Pennsylvania) and Dr. Alessia Fornoni (University of Miami) for an in-depth conversation on the evolving landscape of Focal Segmental Glomerulosclerosis (FSGS).

The first episode of this three-part FSGS series explores the transition from traditional histological classifications to a more precise clinical and molecular understanding of the disease. Dr. Campbell and Dr. Fornoni discuss the definition and pathogenesis of FSGS as well as clinical management and the future of treatment. 

In this episode of KDIGO Conversations in Nephrology, Dr. Kirk Campbell speaks with Dr. Alessia Fornoni about the evolving understanding of focal segmental glomerulosclerosis (FSGS) as a podocytopathy driven by podocyte injury. The discussion explores advances in FSGS classification, the role of angiotensin II and endothelin-1 signaling in disease progression, emerging insights into disease mechanisms, and how new targeted therapies may help preserve podocyte function and slow the progression of kidney disease.

This episode is part of a special three-part KDIGO Conversations in Nephrology series exploring advances in podocyte biology, disease mechanisms, emerging therapies, and the evolving clinical management of FSGS.

This final episode in KDIGO’s four-part IgAN series focuses on the challenges and opportunities of implementing the updated KDIGO IgAN Guideline in clinical practice.
The conversation examines a shifting treatment paradigm that emphasizes earlier intervention and simultaneous, multi-targeted therapy, while addressing persistent barriers to guideline adoption, including gaps in disease awareness, diagnostic precision, and risk stratification.
Drawing on insights from recent clinical trials, the discussion also explores how emerging evidence is shaping therapeutic decision-making, highlights priority areas for future IgAN research, and considers what continued innovation may mean for improving long-term patient outcomes.
The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, US), and features Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US). Previous episodes in the series feature KDIGO IgAN Guideline Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, US), Shikha Wadwani, MD (Cedars Sinai, US), Andrew Lazar, MD (University Hospitals of Cleveland, US), and Gaia Coppock, MD (University of Pennsylvania Medicine, US).

This podcast series was supported by Travere.